Dr. Jennifer Tseng, MD
Claim this profileOrlando Health Cancer Institute
Area of expertise
Non-Small Cell Lung Cancer
Jennifer Tseng, MD has run 5 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Lung Cancer
Jennifer Tseng, MD has run 3 trials for Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Orlando Health Cancer Institute
City Of Hope
Clinical Trials Jennifer Tseng, MD is currently running
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Personalized Adaptive Novel Agents
for Breast Cancer
This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
Recruiting
1 award
Phase 2
16 criteria
More about Jennifer Tseng, MD
Clinical Trial Related
11 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Jennifer Tseng, MD has experience with
- Pembrolizumab
- Da Vinci SP Surgical System
- Open NSM
- Cisplatin
- Nivolumab
- Image Guided Radiation Therapy
Breakdown of trials Jennifer Tseng, MD has run
Non-Small Cell Lung Cancer
Lung Cancer
Breast Cancer
Squamous Cell Carcinoma
Breast Disorder
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer Tseng, MD specialize in?
Jennifer Tseng, MD focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage II patients, or patients who are Stage III.
Is Jennifer Tseng, MD currently recruiting for clinical trials?
Yes, Jennifer Tseng, MD is currently recruiting for 2 clinical trials in Orlando Florida. If you're interested in participating, you should apply.
Are there any treatments that Jennifer Tseng, MD has studied deeply?
Yes, Jennifer Tseng, MD has studied treatments such as Pembrolizumab, da Vinci SP Surgical System, Open NSM.
What is the best way to schedule an appointment with Jennifer Tseng, MD?
Apply for one of the trials that Jennifer Tseng, MD is conducting.
What is the office address of Jennifer Tseng, MD?
The office of Jennifer Tseng, MD is located at: Orlando Health Cancer Institute, Orlando, Florida 32806 United States. This is the address for their practice at the Orlando Health Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.